Contents
Clinical research in West Virginia looks at new ways to treat, detect, or prevent diseases. Treatments can include new medications or a combination of drugs. But, it can also study different medical devices and surgical procedures.
We are here to bridge that gap between research facilities and people willing to participate. Our platform is designed to help you find a clinical trial designed just for you.
Clinical Trials For Disease Areas in West Virginia
To address the diverse healthcare needs of its population, clinical research trials in West Virginia study different disease areas. Some of these include cancer research, studies on asthma, cardiovascular diseases, metabolic disorders, oral health, and rural health disparities.
Doctors at West Virginia University were the first to treat a patient with a new antimicrobial medication. This is the first time the PLG0206 drug has been tested on patients with periprosthetic joint infections. The drug can help address bacterial pathogens that can’t be treated with regular antibiotics.
You too can play a vital role in the future of healthcare. Volunteer for a clinical trial in West Virginia and help take medical progress to new heights!
Caris Biorepository Research Protocol
Recruiting
The Biorepository for Caris Life Sciences is designed for the purpose of making quality biospecimens and associated clinical data available for research studies related to advancing precision medicine and improving care for patients.
The Caris Biorepository is a repository of prospectively collected biological specimens and associated clinical and demographic data gathered from multiple sources to be stored, used and shared for research. Caris Life Sciences will maintain the data and specimens... Read More
The Biorepository for Caris Life Sciences is designed for the purpose of making quality biospecimens and associated clinical data available for research studies related to advancing precision medicine and improving care for patients.
The Caris Biorepository is a repository of prospectively collected biological specimens and associated clinical and demographic data gathered from multiple sources to be stored, used and shared for research. Caris Life Sciences will maintain the data and specimens and will control access to and use of the information and specimens by multiple individuals for multiple purposes which may evolve over time. Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/21/2020
Locations: CAMC Clinical Trials, Charleston, West Virginia
CAMC Clinical Trials, Charleston, West Virginia
Conditions: Cancer
Safety Study of Unlicensed IND Cord Blood Units Manufactured by the National Cord Blood Program for Unrelated Transplantation
Recruiting
This study will evaluate the safety of infusion of the investigational cord blood units by carefully documenting all infusion-related problems.
This study will evaluate the safety of infusion of the investigational cord blood units by carefully documenting all infusion-related problems. Read Less
Gender:
ALL
Ages:
All
Trial Updated:
04/17/2024
Locations: West Virginia University Hospitals Inc, Morgantown, West Virginia
West Virginia University Hospitals Inc, Morgantown, West Virginia
Conditions: Infusion Reactions
RSSearch Patient Registry-Long Term Study of Use of SRS/SBRT
Recruiting
The RSSearch® Registry is an international multi-year database designed to track SRS/SBRT (Stereotactic Radiosurgery/Stereotactic Body Radiation Therapy) utilization, treatment practices and outcomes to help determine, over time, the most effective use of these systems in management of patients with life threatening tumors and other diseases. (This study was formally called ReCKord and included the CyberKnife only; The ReCKord study continues as a CyberKnife subset of RSSearch.)
The RSSearch® Registry is an international multi-year database designed to track SRS/SBRT (Stereotactic Radiosurgery/Stereotactic Body Radiation Therapy) utilization, treatment practices and outcomes to help determine, over time, the most effective use of these systems in management of patients with life threatening tumors and other diseases. (This study was formally called ReCKord and included the CyberKnife only; The ReCKord study continues as a CyberKnife subset of RSSearch.) Read Less
Gender:
ALL
Ages:
All
Trial Updated:
09/17/2024
Locations: St. Mary's Medical Center, Huntington, West Virginia
St. Mary's Medical Center, Huntington, West Virginia
Conditions: Neoplasms, Arteriovenous Malformation of Central Nervous System, Trigeminal Neuralgia
LOWER: Lomitapide Observational Worldwide Evaluation Registry
Recruiting
This global product exposure registry is a multicentre, long-term, prospective, observational cohort study (exposure registry), designed to evaluate the long term safety and effectiveness of lomitapide.
This global product exposure registry is a multicentre, long-term, prospective, observational cohort study (exposure registry), designed to evaluate the long term safety and effectiveness of lomitapide. Read Less
Gender:
ALL
Ages:
All
Trial Updated:
03/11/2024
Locations: West Virginia University Medicine, Morgantown, West Virginia
West Virginia University Medicine, Morgantown, West Virginia
Conditions: Homozygous Familial Hypercholesterolemia
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
Recruiting
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-sma... Read More
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation. Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/29/2024
Locations: United Hospital Center, Bridgeport, West Virginia +6 locations
United Hospital Center, Bridgeport, West Virginia
West Virginia University Charleston Division, Charleston, West Virginia
Edwards Comprehensive Cancer Center, Huntington, West Virginia
WVUH-Berkely Medical Center, Martinsburg, West Virginia
West Virginia University Healthcare, Morgantown, West Virginia
Camden Clark Medical Center, Parkersburg, West Virginia
Wheeling Hospital/Schiffler Cancer Center, Wheeling, West Virginia
Conditions: ALK Gene Rearrangement, ALK Gene Translocation, ALK Positive, Stage IB Non-Small Cell Lung Carcinoma AJCC v7, Stage II Non-Small Cell Lung Cancer AJCC v7, Stage IIA Non-Small Cell Lung Carcinoma AJCC v7, Stage IIB Non-Small Cell Lung Carcinoma AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7
Study to Determine the Pharmacokinetics and Pharmacodynamic Effects of Phenylephrine on BP Via IV
Recruiting
The primary objective of this study is to evaluate the dose effect of Phenylephrine Hydrochloride Injection on the treatment of clinically relevant decreased blood pressure in the pediatric population, ≥12 to 16 year old patients undergoing general and neuraxial anesthesia.
The secondary objectives are to describe changes in blood pressure and heart rate, time to onset and to maximal response, and the duration of response; to assess the safety of the product in this population; and to character... Read More
The primary objective of this study is to evaluate the dose effect of Phenylephrine Hydrochloride Injection on the treatment of clinically relevant decreased blood pressure in the pediatric population, ≥12 to 16 year old patients undergoing general and neuraxial anesthesia.
The secondary objectives are to describe changes in blood pressure and heart rate, time to onset and to maximal response, and the duration of response; to assess the safety of the product in this population; and to characterize the pharmacokinetics of phenylephrine hydrochloride. Read Less
Gender:
ALL
Ages:
Between 12 years and 16 years
Trial Updated:
07/22/2024
Locations: Ruby Memorial Hospital, Morgantown, West Virginia
Ruby Memorial Hospital, Morgantown, West Virginia
Conditions: Hypotension
Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML
Recruiting
The primary objectives of this study are to assess: (1) whether the combination of BP1001 plus venetoclax plus decitabine provides greater efficacy (Complete Remission \[CR\], Complete Remission with incomplete hematologic recovery \[CRi\], Complete Remission with partial hematologic recovery \[CRh\], than venetoclax plus decitabine alone (by historical comparison) in participants with untreated AML that cannot or elect not to be treated with more intensive chemotherapy; (2) whether BP1001-based... Read More
The primary objectives of this study are to assess: (1) whether the combination of BP1001 plus venetoclax plus decitabine provides greater efficacy (Complete Remission \[CR\], Complete Remission with incomplete hematologic recovery \[CRi\], Complete Remission with partial hematologic recovery \[CRh\], than venetoclax plus decitabine alone (by historical comparison) in participants with untreated AML that cannot or elect not to be treated with more intensive chemotherapy; (2) whether BP1001-based treatment provides greater efficacy (CR, CRi, CRh) than intensive chemotherapy (by historical comparison) in participants with refractory/relapsed AML. Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/06/2025
Locations: West Virginia University/Mary Babb Randolph Cancer Center, Morgantown, West Virginia
West Virginia University/Mary Babb Randolph Cancer Center, Morgantown, West Virginia
Conditions: Acute Myeloid Leukemia (AML)
Prospective Evaluation of Adjusted Body Weight Dosing of Acyclovir in Obesity
Recruiting
Patients receiving acyclovir as standard of care will be enrolled into this study. The currently recommended dosing strategy at our institution for obese patients is to receive intravenous acyclovir dosed per an adjusted body weight \[IBW + 0.4(TBW-IBW)\]. They will have blood drawn once prior to the first dose of acyclovir and 10 times thereafter, over a total time period of 12 hours. These patients will already be hospitalized for other reasons, and will not be required to make additional trip... Read More
Patients receiving acyclovir as standard of care will be enrolled into this study. The currently recommended dosing strategy at our institution for obese patients is to receive intravenous acyclovir dosed per an adjusted body weight \[IBW + 0.4(TBW-IBW)\]. They will have blood drawn once prior to the first dose of acyclovir and 10 times thereafter, over a total time period of 12 hours. These patients will already be hospitalized for other reasons, and will not be required to make additional trips to the hospital. A total of approximately 4-5 tablespoons of blood will be drawn for this study. Ten obese patients and 10 matched control (non-obese) patients will be enrolled. Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/26/2025
Locations: West Virginia University Hospitals, Morgantown, West Virginia
West Virginia University Hospitals, Morgantown, West Virginia
Conditions: Obesity
An Active and Placebo-Controlled Study of Brazikumab in Participants With Moderately to Severely Active Ulcerative Colitis
Recruiting
The present study D5272C00001 (Legacy # 3151-201-008) seeks to evaluate the efficacy and safety of brazikumab versus placebo in patients with moderately to severely active UC and will include assessments of clinical responses as demonstrated by improvement of symptoms and of colonic mucosal appearance as observed on endoscopy.
The present study D5272C00001 (Legacy # 3151-201-008) seeks to evaluate the efficacy and safety of brazikumab versus placebo in patients with moderately to severely active UC and will include assessments of clinical responses as demonstrated by improvement of symptoms and of colonic mucosal appearance as observed on endoscopy. Read Less
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
01/19/2021
Locations: Research Site, Huntington, West Virginia
Research Site, Huntington, West Virginia
Conditions: Ulcerative Colitis
Study to Evaluate The Safety and Efficacy of Balovaptan in Patients With Acute Ischemic Stroke at High Risk of Developing Malignant Brain Edema
Recruiting
This study is designed to evaluate the safety, efficacy, and pharmacokinetics of balovaptan compared with placebo in participants with acute ischemic stroke (AIS) at risk of developing malignant cerebral edema (MCE)
This study is designed to evaluate the safety, efficacy, and pharmacokinetics of balovaptan compared with placebo in participants with acute ischemic stroke (AIS) at risk of developing malignant cerebral edema (MCE) Read Less
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
04/04/2022
Locations: West Virginia University Hospital, Morgantown, West Virginia
West Virginia University Hospital, Morgantown, West Virginia
Conditions: Acute Ischemic Stroke
Paid Clinical Trials in West Virginia
Do you need medical treatment, but can’t afford it? Whether you want to participate in trials to improve medicine or get access to new treatments, paid clinical trials in West Virginia can come with a financial benefit. You can get compensated for offering valuable information.
WV paid clinical trials offer anywhere from a couple hundred to more than ten thousand dollars. But, the payment will vary from one trial to another. Check the details of the trial before you apply.
Clinical Trials For Health Volunteers in West Virginia
People join clinical trials for various reasons. Healthy volunteers apply to help advance scientific knowledge. While those with a specific illness often look for a new treatment alternative.
Research teams in West Virginia are here to provide top-quality care for anyone who wants to participate. Together, we can push the boundaries of medicine. Volunteer for a clinical trial today!
No trials could be found at this time
Medical Discoveries and Innovation in West Virginia
West Virginia clinical research has made some remarkable contributions to the field of medicine. Experts are leveraging technology and collaborating with scientists from other institutions to improve healthcare. Some of these advancements include:
- Medicaid Programs: West Virginia was recognized for innovations in its Medicaid program. The program obtained the 2022 Medicaid Innovation Award. The program was recognized for offering care coordination to young people in foster care.
- Substance Use Disorder Research: West Virginia has been involved in studies and interventions about managing substance use disorders. The studies have helped find solutions that can accommodate a wide range of patients.
- Cardiovascular research: The WVU Heart and Vascular Institute is at the forefront of studies on heart health. Especially in areas related to heart disease prevention and management. Their data has helped improve patient outcomes in the U.S. and around the world.
Why West Virginia Is A Great Place For Clinical Research
Clinical research in West Virginia can thrive with diverse population data. About 91.5% of its residents are White, 3.6% are Black, 1.9% are Hispanic, 1.9% are Multiracial, 0.9% are Asian, and 0.2% are American Indian.